{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"cortisone-reductase-deficiency-2","columns":[{"gene":"","key":"population-fa5b28c54934bf21a74a","label":"Cortisone reductase deficiency 2","mondoId":"MONDO:0013842","onsetQualifier":null,"originColumnKey":"MONDO:0013842/OMIM:614662","originalViews":[{"key":"MONDO:0013842/OMIM:614662","label":"Cortisone reductase deficiency 2","scopeLabel":"OMIM:614662","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["01c0b8f5371e4aab28999060a061184addc73078ae62865567201e60332402d9","311d4e5d5b281cb649ab9db9e3c3fbf8b3bf94d3d65e84a89c5c9345a02100b5","7473165cf2ad2cfdcfb951816dbf6562d128c0a821988d453eefff7030b4eb03","894143847b97d0d3eb1bc0322a7a43cf39a09f437fc20ff24f0c494f75c48178","96c8abbfe6519d91ea247d3d44a09a490e0162cc830f19fea636f9c838fd68df","ccfc03bc2978cc2b4abc85da1816309675363472adfba11c525c6525c7898bc6","f8ad6b7602bf8a341c39f5f07d6cfa47916ff886c11eba1552b2400321362cc6"],"recordQualifiers":{},"scopeLabel":"OMIM:614662","sourceIds":["OMIM:614662"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-fa5b28c54934bf21a74a"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0000956","HP:0005616","HP:0000855","HP:6000185","HP:0001513","HP:0012411","HP:6001080"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":7,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":7,"sourceGroups":{"published":7}},"features":[{"hpoId":"HP:0000956","label":"Acanthosis nigricans","primary":true},{"hpoId":"HP:0005616","label":"Accelerated skeletal maturation","primary":true},{"hpoId":"HP:0000855","label":"Insulin resistance","primary":true},{"hpoId":"HP:6000185","label":"Low tetrahydrocortisol (THF) plus 5-alpha-THF/tetrahydrocortisone (THE) ratio","primary":true},{"hpoId":"HP:0001513","label":"Obesity","primary":true},{"hpoId":"HP:0012411","label":"Premature pubarche","primary":true},{"hpoId":"HP:6001080","label":"Reduced urine tetrahydrocortisol plus 5-alpha-THF to tetrahydrocortisone ratio","primary":true}],"ledeHtml":"Decreased activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 due to inactivating mutation(s) in the HSD11B1 gene. The condition is characterized by hyperandrogenism as a result of increased adrenocorticotropic hormone stimulation of the adrenal gland due to failure of cortisol-mediated down-regulation, and is clinically indistinguishable from H6PD deficiency.","mondoId":"MONDO:0013842","node":{"canonicalSlug":"cortisone-reductase-deficiency-2","comparisons":[{"documentSha256":"16701474529fa23e39b3f1db967553befa4dc4f301859f9f73ae93e83ceaabd8","key":"legacy-cortisone-reductase-deficiency","kind":"legacy","label":"cortisone reductase deficiency","memberIds":["MONDO:0000193","MONDO:0011503","MONDO:0013842"],"mondoId":"MONDO:0000193","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/cortisone-reductase-deficiency.16701474529fa23e39b3f1db967553befa4dc4f301859f9f73ae93e83ceaabd8.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"definition-only","matchMethod":"same-ontology-node","name":"cortisone reductase deficiency 2","paragraphs":["Decreased activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 due to inactivating mutation(s) in the HSD11B1 gene. The condition is characterized by hyperandrogenism as a result of increased adrenocorticotropic hormone stimulation of the adrenal gland due to failure of cortisol-mediated down-regulation, and is clinically indistinguishable from H6PD deficiency."],"scope":"exact","source":"MONDO","upstream":"NCIT:C131084","url":"https://monarchinitiative.org/MONDO:0013842"},"ownColumnKeys":["population-fa5b28c54934bf21a74a"],"publication":"published","relationships":[{"kind":"parent","label":"cortisone reductase deficiency","mondoId":"MONDO:0000193","slug":"cortisone-reductase-deficiency"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"Public source record is not available in the frozen inputs","source":"GARD","url":"https://rarediseases.info.nih.gov/diseases/15830"}],"translation":"published"},"records":[{"frequencyKind":"count","key":"01c0b8f5371e4aab28999060a061184addc73078ae62865567201e60332402d9","raw":{"aspect":"P","body_system":"endocrine","disease_id":"OMIM:614662","disease_name":"Cortisone reductase deficiency 2","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:6000185","is_excluded":false,"label":"Low tetrahydrocortisol (THF) plus 5-alpha-THF/tetrahydrocortisone (THE) ratio","onset_id":null,"reference":"PMID:21325058","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"311d4e5d5b281cb649ab9db9e3c3fbf8b3bf94d3d65e84a89c5c9345a02100b5","raw":{"aspect":"P","body_system":"growth","disease_id":"OMIM:614662","disease_name":"Cortisone reductase deficiency 2","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0001513","is_excluded":false,"label":"Obesity","onset_id":null,"reference":"PMID:21325058","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"7473165cf2ad2cfdcfb951816dbf6562d128c0a821988d453eefff7030b4eb03","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"OMIM:614662","disease_name":"Cortisone reductase deficiency 2","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0005616","is_excluded":false,"label":"Accelerated skeletal maturation","onset_id":null,"reference":"PMID:21325058","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"894143847b97d0d3eb1bc0322a7a43cf39a09f437fc20ff24f0c494f75c48178","raw":{"aspect":"P","body_system":"skin","disease_id":"OMIM:614662","disease_name":"Cortisone reductase deficiency 2","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0000956","is_excluded":false,"label":"Acanthosis nigricans","onset_id":null,"reference":"PMID:21325058","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"96c8abbfe6519d91ea247d3d44a09a490e0162cc830f19fea636f9c838fd68df","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:614662","disease_name":"Cortisone reductase deficiency 2","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0000855","is_excluded":false,"label":"Insulin resistance","onset_id":null,"reference":"PMID:21325058","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"ccfc03bc2978cc2b4abc85da1816309675363472adfba11c525c6525c7898bc6","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:614662","disease_name":"Cortisone reductase deficiency 2","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:6001080","is_excluded":false,"label":"Reduced urine tetrahydrocortisol plus 5-alpha-THF to tetrahydrocortisone ratio","onset_id":null,"reference":"PMID:21325058","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"f8ad6b7602bf8a341c39f5f07d6cfa47916ff886c11eba1552b2400321362cc6","raw":{"aspect":"P","body_system":"endocrine","disease_id":"OMIM:614662","disease_name":"Cortisone reductase deficiency 2","evidence":"PCS","frequency_raw":"1/2","hpo_id":"HP:0012411","is_excluded":false,"label":"Premature pubarche","onset_id":null,"reference":"PMID:21325058","source_release":"2026-06-23"},"sourceGroups":["published"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0013842\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>definition-only</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>same-ontology-node</dd><dt>Upstream attribution</dt><dd>NCIT:C131084</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Decreased activity of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 due to inactivating mutation(s) in the HSD11B1 gene. The condition is characterized by hyperandrogenism as a result of increased adrenocorticotropic hormone stimulation of the adrenal gland due to failure of cortisol-mediated down-regulation, and is clinically indistinguishable from H6PD deficiency.</p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0013842\" rel=\"noreferrer\">MONDO</a></p>","key":"overview","title":"Brief description"}],"sharedSources":[],"slug":"cortisone-reductase-deficiency-2","sourceDocuments":[{"name":"MONDO: cortisone reductase deficiency 2","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0013842"}],"sourceNote":"","synonyms":["11-beta-hydroxysteroid dehydrogenase type 1 deficiency","cortisone reductase deficiency 2","cortisone reductase deficiency caused by mutation in HSD11B1","cortisone reductase deficiency type 2","CORTRD2","HSD11B1 cortisone reductase deficiency"],"takeawayHtml":"","title":"cortisone reductase deficiency 2"},"schemaVersion":1}
